Government-Owned Inventions; Availability for Licensing, 24023 [2024-07278]

Download as PDF Federal Register / Vol. 89, No. 67 / Friday, April 5, 2024 / Notices Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Initial Review Group; Fellowships in Kidney, Urology, and Hematology DDK–G Fellowships in Kidney, Urology, and Hematology. Date: June 12, 2024. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015 (In-Person). Contact Person: Xiaodu Guo, M.D., Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7023, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–4719, guox@extra.niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology khammond on DSKJM1Z7X2PROD with NOTICES Where L is optionally present and is a C1-C6 alkyl group, a C1-C6 alkoxy group, a -(CH2CH2O)n- group where n is an integer from 1 to 6, a phenyl group, or a benzyl group, each of which is optionally substituted. B is a substituted or unsubstituted aromatic or heteroaromatic substituent, and where X1 is S(=O) or S; Y1 is N or CR4; and each of R1-R7 is independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, perfluoro C1-C6 alkyl, perfluoro C1-C6 alkoxy, halo, -CN, -OH, -COOR8, substituted or unsubstituted aromatic, or substituted or unsubstituted heteroaromatic, and each R8 independently is hydrogen, C1-C6 alkyl, phenyl, or benzyl. Potential Commercial Applications: VerDate Sep<11>2014 16:44 Apr 04, 2024 Jkt 262001 and Hematology Research, National Institutes of Health, HHS) Dated: April 2, 2024. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–07279 Filed 4–4–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by contacting Michael Shmilovich, Esq, MS, CLP; 301–435–5019; michael.shmilovich@nih.gov, at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, SUMMARY: • • • • • antivirals therapeutics ESCRT complex formation prazole antifungal Development Stage: • Early stage Inventors: Nico Tjandra (NHLBI), Carol Carter (Stonybrook), Rolf E. Swenson (NHLBI), David Nyenhuis (NHLBI), Natarajan Raju (NHLBI), Chandra Mushti, (NHLBI), and Venkata Sabbasani (NHLBI). Intellectual Property: HHS Reference No. E–239–2023–0; U.S. Provisional Patent Application No. 63/545,080 filed October 20, 2023. Publication: D. A. Nyenhuis, S. Watanabe, R. Bernstein, R. E. Swenson, PO 00000 Frm 00063 Fmt 4703 Sfmt 9990 MSC2479, Bethesda, MD 20892–2479. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404. Technology description follows. Prazole-Based Antiviral Therapeutics: Available for licensing and commercial development is a patent estate that covers prazole based compounds and their methods of use as antiviral therapeutics. Prazoles are benzimidazole derivatives generally marketed as stomach-acid reducers, owing to their ability to inhibit the H+/ K+ ATPases (proton pumps) of the parietal cells in the stomach epithelium. Prazoles can inhibit the egress of several viral targets: HIV–1, HSV–1 and –2, MAYV, and EBV by interfering with the ESCRT complex in the formation of exosomes. In that respect, the target for inhibition of these viruses is Tumor susceptibility gene 101 (Tsg101), a member of the ESCRT–I complex. The N-terminal ubiquitin E2 variant (UEV) domain of Tsg101 has both ubiquitin and P[T/S]AP motif binding sites, where the prazole binds to C73 in the middle of the ubiquitin-binding site, sterically inhibiting the Ub-Tsg101 interaction. By way of example, and not limitation, a prazole compound according to this invention can take on the follow core structure: N. Raju, V. R. Sabbasani, C. Mushti, D.Y. Lee, C. Carter, N. Tjandra, ‘‘Structural Relationships to Efficacy for PrazoleDerived Antivirals.’’ Adv. Sci. 2024, 2308312. https://doi.org/10.1002/advs. 202308312. Licensing Contact: Michael Shmilovich, Esq, MS, CLP; 301–435– 5019; michael.shmilovich@nih.gov. Dated: April 2, 2024. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2024–07278 Filed 4–4–24; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\05APN1.SGM 05APN1 EN05AP24.048</GPH> amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. 24023

Agencies

[Federal Register Volume 89, Number 67 (Friday, April 5, 2024)]
[Notices]
[Page 24023]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07278]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by contacting Michael Shmilovich, Esq, MS, CLP; 301-435-5019; 
[email protected], at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of Technology 
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479. 
A signed Confidential Disclosure Agreement may be required to receive 
any unpublished information.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404. Technology description follows. Prazole-Based 
Antiviral Therapeutics:
    Available for licensing and commercial development is a patent 
estate that covers prazole based compounds and their methods of use as 
antiviral therapeutics. Prazoles are benzimidazole derivatives 
generally marketed as stomach-acid reducers, owing to their ability to 
inhibit the H+/K+ ATPases (proton pumps) of the parietal cells in the 
stomach epithelium. Prazoles can inhibit the egress of several viral 
targets: HIV-1, HSV-1 and -2, MAYV, and EBV by interfering with the 
ESCRT complex in the formation of exosomes. In that respect, the target 
for inhibition of these viruses is Tumor susceptibility gene 101 
(Tsg101), a member of the ESCRT-I complex. The N-terminal ubiquitin E2 
variant (UEV) domain of Tsg101 has both ubiquitin and P[T/S]AP motif 
binding sites, where the prazole binds to C73 in the middle of the 
ubiquitin-binding site, sterically inhibiting the Ub-Tsg101 
interaction. By way of example, and not limitation, a prazole compound 
according to this invention can take on the follow core structure:
[GRAPHIC] [TIFF OMITTED] TN05AP24.048

    Where L is optionally present and is a C1-C6 
alkyl group, a C1-C6 alkoxy group, a -
(CH2CH2O)n- group where n is an 
integer from 1 to 6, a phenyl group, or a benzyl group, each of which 
is optionally substituted. B is a substituted or unsubstituted aromatic 
or heteroaromatic substituent, and where

X1 is S(=O) or S;
Y1 is N or CR4; and
each of R1-R7 is independently selected from 
hydrogen, C1-C6 alkyl, C1-
C6 alkoxy, perfluoro C1-C6 alkyl, 
perfluoro C1-C6 alkoxy, halo, -CN, -OH, -
COOR8, substituted or unsubstituted aromatic, or 
substituted or unsubstituted heteroaromatic, and
each R8 independently is hydrogen, C1-
C6 alkyl, phenyl, or benzyl.

    Potential Commercial Applications:

 antivirals
 therapeutics
 ESCRT complex formation
 prazole
 antifungal

    Development Stage:

 Early stage

    Inventors: Nico Tjandra (NHLBI), Carol Carter (Stonybrook), Rolf E. 
Swenson (NHLBI), David Nyenhuis (NHLBI), Natarajan Raju (NHLBI), 
Chandra Mushti, (NHLBI), and Venkata Sabbasani (NHLBI).
    Intellectual Property: HHS Reference No. E-239-2023-0; U.S. 
Provisional Patent Application No. 63/545,080 filed October 20, 2023.
    Publication: D. A. Nyenhuis, S. Watanabe, R. Bernstein, R. E. 
Swenson, N. Raju, V. R. Sabbasani, C. Mushti, D.-Y. Lee, C. Carter, N. 
Tjandra, ``Structural Relationships to Efficacy for Prazole-Derived 
Antivirals.'' Adv. Sci. 2024, 2308312. https://doi.org/10.1002/advs.202308312.
    Licensing Contact: Michael Shmilovich, Esq, MS, CLP; 301-435-5019; 
[email protected].

    Dated: April 2, 2024.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2024-07278 Filed 4-4-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.